National
Defense leaders support open service
Adm. Michael Mullen (DC Agenda photo by Michael Key)
Top Pentagon leaders announced Tuesday their support for allowing gays, lesbians and bisexuals to serve openly in the U.S. military while unveiling new plans for a working group that will examine the impact of such a change in the armed forces.
Defense Secretary Robert Gates and Chairman of the Joint Chiefs of Staff Adm. Michael Mullen made the remarks in the first Senate hearing in 17 years dedicated to the issue of gays in the military.
Mullen told the Senate Armed Services Committee that he favors allowing gays to serve openly as a matter of fairness for those who are serving in the armed forces.
“Speaking for myself, and myself only, it is my personal belief that allowing gays and lesbians to serve openly is the right thing to do,” Mullen said. “No matter how I look at this issue, I cannot escape … the fact that we have in place a policy that forces young men and women to lie about who they are in order to defend their fellow citizens.”
Gates similarly expressed support for ending “Don’t Ask, Don’t Tell,” noting President Obama’s last week restated his commitment to repealing the law in his State of the Union address.
“I fully support the president’s decision,” he said. “The question before us is not whether the military decides to makes this change, but how we best prepare for it. We have received our orders from the commander-in-chief and we are moving out accordingly.”
Mullen and Gates’ support for allowing gays to serve in the U.S. military stands in stark contrast to how military leaders in 1993 opposed open service and favored “Don’t Ask, Don’t Tell.”
The Senate panel received Mullen and Gates’ endorsement of allowing gays to serve openly in the U.S. military with mixed reactions — with those opposing “Don’t Ask, Don’t Tell” applauding them and those supporting the policy expressing their discontent.
Sen. John McCain (R-Ariz.), ranking Republican on the committee and strong proponent of “Don’t Ask, Don’t Tell,” said he was “deeply disappointed” with Gates’ testimony and said it showed his bias on the issue.
“It would be far more appropriate, I say with great respect, to determine whether repeal of this law is appropriate and what the effects it would have on the readiness and the effectiveness of the military before deciding on whether we should repeal the law or not,” he said.
Sen. Jeff Sessions (R-Ala.) noted Mullen only came out in favor of allowing open service after Obama announced his intent to repeal “Don’t Ask, Don’t Tell,” suggesting Mullen was taking that position to fall in line with his superior.
Sessions said Mullen’s position would interfere with his subordinates’ ability to evaluate “Don’t Ask, Don’t Tell” and the implication of its repeal.
“I guess, if it was a trial, we would perhaps raise the undue command influence defense flag,” Sessions said.
But Senate Armed Services Committee Chairman Carl Levin (D-Mich.) came to the defense of Mullen, saying the admiral was showing leadership and acting as required by a Senate-confirmed nominee by expressing his personal opinion.
“It was clear to me and, I think, clear to most of us that you think this is a view that you hold in your conscience and not given to us because you were directed to by anybody, including the commander-in-chief,” Levin said.
Gates and Mullen expressed support for a change in policy while at the same time highlighting the importance of a new Pentagon working group that would examine the issue.
Mullen said he didn’t know fully what impact ending “Don’t Ask, Don’t Tell” would have throughout the armed forces — especially in a time of two wars — and said further investigation would bring to light those implications.
“That there will be legal, social and perhaps even infrastructure changes to be made certainly seems plausible,” Mullen said. “We would all like to have a better handle on these types of concerns.”
Gates unveiled new plans for a working group that he said would examine the implications of ending “Don’t Ask, Don’t Tell.” By the end of this year, the group is charged with producing recommendations in the form of an implementation plan in the event Congress decides to repeal the statute.
Defense Department General Counsel Jeh Jonson and Gen. Carter Ham, commander of U.S. Army Europe, have been chosen to lead this working group, Gates said.
The working group, Gates said, would be charged with reaching out to the force to understand their views about repeal, examining changes in regulations and policy that need to be made and looking at the potential impact of a change in law on military readiness.
To supplement the efforts of this working group, Gates said the Pentagon will ask the RAND Corp. to update its 1993 study on the impact of allowing gays to serve in the military, which at the time found that open service wouldn’t be detrimental to the U.S. military.
In addition to the working group, Gates said he’s directed the Pentagon to review the regulations used to implement “Don’t Ask, Don’t Tell” and, within 45 days, present recommendations that could be applied under existing law to “enforce this policy in a more humane and fair manner.”
“You may recall that I asked the Department’s general counsel to conduct a preliminary review of this matter last year,” Gates said. “Based on that preliminary review, we believe that we have a degree of latitude within the existing law to change our internal procedures in a manner that is more appropriate and fair to our men and women in uniform.”
While the recommendations aren’t yet complete, Gates said the Pentagon is considering a number of options that could allow for greater latitude on discharging gay service members under current law.
Gates said it’s possible to change implementation of current law by raising the rank of officers who are authorized to either initiate or conduct inquiries under “Don’t Ask, Don’t Tell.” He also said officials can “raise the bar” on what is considered credible information or who is considered a credible source to start an inquiry on a service member.
“Overall, we can reduce the instances in which the service member who is trying to serve the country honorably is outed by a third-person with the motive to harm the service member,” Gates said.
Many LGBT activists praised Gates and Mullen for coming out in favor of allowing gays to serve openly in the U.S. military and working to adjust the rules for discharges. Still, activists maintain that full repeal is still necessary.
Lt. Dan Choi, a gay U.S. Army infantry soldier who’s facing discharge after publicly coming out last year, told DC Agenda after the hearing that “there will be some impact” by the interim changes proposed by Gates, but said it’s “missing the point.”
“When you still have people that are lying about who they are, you haven’t solved the root of the problem,” Choi said. “‘Don’t Ask, Don’t Tell’ is the establishment of a closeted policy, and I don’t think that anybody has to be closeted in our military.”
Lawmakers considering ‘Don’t Ask’ moratorium
Gates’ announcement on the formation of a new working group raises questions about whether Congress will act this year to repeal the law or instead wait until the working group completes its review.
Levin suggested he may include language that would change “Don’t Ask, Don’t Tell” in the upcoming defense authorization bill.
After Sen. Joseph Lieberman (I-Conn.) made a comment that senators need to find 60 votes to pass repeal legislation, Levin replied, “Unless there’s a provision in the defense authorization bill that goes to the floor, which would then require an amendment to strike it from the bill, in which case, the 60-vote rule would be turning the other way.”
Following the hearing, Levin told reporters that it’s possible to include in the defense authorization bill a moratorium on “Don’t Ask, Don’t Tell” that would be in place until the Pentagon completes its study.
“If we throw a moratorium on it, then what I consider to be a slow pace then would be more practical,” he said.
Asked whether he’s ruled out actual repeal in the defense authorization bill in favor of a moratorium, Levin replied, “I haven’t ruled anything out.”
Also foreseeing the possibility of repeal this year is Sen. Kirsten Gillibrand (D-N.Y.), one of the most vocal proponents in Congress of overturning “Don’t Ask, Don’t Tell.”
After the hearing, she told reporters she doesn’t think the time Gates is asking for review “will affect legislative progress” and that “we can actually write the bill and pass the bill now.”
“I think all that Adm. Mullen and Secretary Gates were saying is that they want to have a sensitivity to the impact it will have on the military and their families, and to have input in order to decide how to best to implement a policy change,” she said. “So, if they need to take time to do that, that’s fine and appropriate, but it doesn’t mean we can’t pass the repeal now, which is important to move forward on this.”
Gillibrand said she would support the inclusion of a moratorium in the defense authorization bill this year in addition to efforts for outright repeal. She said she thinks there are 60 votes in the Senate for full repeal and recalled how she considered a moratorium amendment last year on “Don’t Ask, Don’t Tell” that she ultimately didn’t introduce.
“When I did my bill on moratorium [and] I counted the votes, the only undecided Democrats at that time said their reasons were they wanted to see leadership in the military, or wanted to see leadership from the president,” she said. “And I think what this hearing brings us is leadership on both.”
But Christopher Neff, deputy executive director of the Palm Center, a think-tank on gays in the military at the University of California, Santa Barbara, was pessimistic about the chances of passing legislation to address “Don’t Ask, Don’t Tell” this year.
He said the Pentagon’s establishment of a working group would make Congress reluctant to take action until the results of its study are known.
“I think that it would be anticipated that many legislators will be waiting to hear what comes out of the study group’s report at the end of the year,” Neff said. “I think that there are enough questions that are being raised that, I think, would be difficult without this study report.”
Whatever effort Congress takes in moving toward repeal this year, lawmakers are set to hear more testimony on “Don’t Ask, Don’t Tell” in later hearings.
Levin told reporters the Senate Armed Services Committee would revisit the issue of gays in the military Feb. 11 and will hear from an “outside panel” of expert witnesses.
He also said he expects senators to ask questions on “Don’t Ask, Don’t Tell” when the service chiefs and service secretaries testify before Congress this month on the president’s budget request.
On the House said, Rep. Susan Davis (D-Calif.), chair of the House Armed Services personnel subcommittee, has scheduled a hearing on “Don’t Ask, Don’t Tell” in March that will follow up on previous testimony the subcommittee heard in 2008.
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Reasons to be optimistic about 2026
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Using movement to boost your mental health during holidays
